TP53 and prostate cancer: In vivo studies have demonstrated that the inhibition of tumor suppressors (such as p16 and p53) and up-regulation of telomerase activity and TERT expression may promote tumorigenesis, including prostate cancer [51, 52], whereas the opposite features underline senescence [53].